DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice

Gene Therapy

Volumn 15, Issue 1, 2008, Pages 61-64

  Mkrtichyan, M ^a   Ghochikyan, A ^a   Loukinov, D ^b   Davtyan, H ^a   Ichim, T E ^c   Cribbs, D H ^d   Lobanenkov, V V ^b   Agadjanyan, M G ^a,d  

^a INSTITUTE FOR MOLECULAR MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c OncoMune Inc   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROTHER OF REGULATOR OF IMPRINTED SITES TRANSCRIPTION FACTOR; CANCER VACCINE; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; PLASMID DNA; QUIL A; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG DOSAGE FORM COMPARISON; DRUG POTENCY; EXPERIMENTAL NEOPLASM; LYMPHOCYTE PROLIFERATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE; TH1 CELL; TUMOR IMMUNITY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BREAST NEOPLASMS; CANCER VACCINES; CELL LINE, TUMOR; DNA-BINDING PROTEINS; GENE THERAPY; IMMUNOTHERAPY; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-18; INTERLEUKIN-4; MICE; MUTATION; NEOPLASM TRANSPLANTATION; RECOMBINANT PROTEINS; SAPONINS; TH1 CELLS; TREATMENT OUTCOME; VACCINES, DNA;

ANIMALIA; MUS;

EID: 37249076017     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303044     Document Type: Article

References (26)

1. Gattinoni L, Powell Jr DJ, Rosenberg SA, Rstifo NP. Adoptive immunotherapy for cancer: Building on success. Nat Rev Immunol 2006; 6: 383-393.
2. Vieweg-J, Su Z, Dahm P, Kusmartsev S. Reversal of tumor-mediated immunosuppression. Clin Cancer Res 2007; 13: 727s-732s.
3. Biragyn A, Tani K, Grimm MC, Weeks S, Kwak LW. Genetic fusion of chemokines, to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999; 17: 253-258.
4. Kim JJ, Trivedi NN, Wilson DM, Mahalingam S, Morrison L, Tsai A et al. Molecular and immunological analysis of genetic prostate. specific antigen (PSA) vaccine (published erratum appears in Oncogene 1999 Apr 8;18(14):2411). Oncogene 1998; 17: 3125-3135.
5. Cohen EP Cancer therapy with DNA-based vaccines. Immunol Lett 2000; 74: 59-65.
6. Monzavi-Karbassi B, Hennings Q, Artaud C, Liu T, Jousheghany F, Pashov A et al. Preclinical studies of carbohydrate mimetic peptide vaccines for breast cancer and melanoma. Vaccine 2007; 25: 3022-3031.
7. Monzavi-Karbassi B, Artaud C, Jousheghany F, Hennings L, Carcel-Trullols J, Shaaf S et al. Reduction of spontaneous metastases through induction of carbohydrate cross-reactive apoptotic antibodies. J Immunol 2005; 174: 7057-7065.
8. Petrovan RJ, Kaplan CD, Reisfeld RA, Curtiss LK. DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 1095-1100.
9. Kaplan CD, Kruger JA, Zhou H, Luo Y, Xiang R, Reisfeld RA. A novel DNA vaccine encoding PDGFRbeta suppresses growth and dissemination of murine colon, lung and breast carcinoma. Vaccine 2006; 24: 6994-7002.
10. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: Review, standardization, and commentary. Cancer Immun 2004; 4: 1.
11. Simpson AJ, Caballero OL, Jungbluth A, Chen Yr, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-625.
12. Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J. Cell Physiol 2003; 194: 272-288.
13. Klenova EM, Morse III HC, Ohlsson R, Lobanenkov W. The novel BORIS+CTCF gene family is uniquely involved in the epigenetics of normal biology and cancer. Semin Cancer Biol 2002; 12: 399-414.
14. Loukinov DI, Pugacheva, E, Vatolin S, Pack SD, Moon H, Chernukhin I et al. BORIS, a novel male germ-line-specific protein associated with epigenetic reprograming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proc Natl Acad Sci USA, 2002; 99: 6806-6811.
15. Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov W, Cribbs DH et al. Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem 2006; 98: 1037-1043.
16. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI et al. Conditional expression of the CTCF-Paralogpus transcriptional factor BORIS in normal cells results in demethylation and depression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res 2005; 65: 7751-7762.
17. Hong JA, Kang Y, Abdullaev Z, Flanagan PT, Pack SD, Fischette MR et al. Reciprocal binding of CTCF and BORIS to the NY-ESO1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res 2005, 05: 7763-7774.
18. Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Pack SD, Movsesyan N et al. Epigenetically acting tumor promoting transcription factor BORIS is widely expressed TAA inducing anti-tumor specific T cell responses J. Immunol 2007; 178: 556-573.
19. Wang H, Hosiawa KA, Min W, Yang J, Zhang X, Garcia B et al. Cytokines regulate the pattern of rejection and susceptibility to cyclosporine therapy in different mouse recipient strains after cardiac allografting. J Immunol 2003; 171: 3823-3836.
20. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164: 6166-6173.
21. Miller FR, Miller BE, Heppner GH. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 1983; 3: 22-31.
22. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of sub-populations of a mouse mammary tumor. Cancer Res 1992; 52: 1399-1405.
23. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999; 17: 163-170.
24. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II. and B7.1 cell-based tumor vaccines. Cancer Res 1998; 58: 1486-1493.
25. Pulaski BA, Terman DS, Khan S, Muller E, Ostrand-Rosenberg S. Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model. Cancer Res 2000; 60: 2710-2715.
26. Prehn RT. On the nature of cancer and why anticancer vaccines don't work. Cancer Cell Int 2005; 5: 25.